Clinical trials: Interferon Deficiency
Vitamin D Deficiency, Coronary Artery Disease
Vitamin D Repletion in Coronary Artery Disease
Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease.
- Conditions
- Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
- Trial name
- NCT01570309
- Testing
- Ergocalciferol, Sugar pill
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seth I. Sokol, M.D.
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network
Sarcoma, Kaposi, HIV Infections
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
To determine the highest tolerated dose of the safety and tolerance of interferon beta (IFN-B) when it is given at the same time as zidovudine (AZT) to patients with early AIDS related Kaposi's sarcoma.
- Trial name
- NCT00000695
- Testing
- Interferon beta-1b, Zidovudine
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Hepatitis C Infection
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV).
- Trial name
- NCT00991289
- Testing
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 68 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infection
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
Primary Objective: To evaluate the efficacy (sustained virological response 12 weeks after end-of-treatment [SVR12]) of 12-week course of an interferon-free regimen combining sofosbuvir and weight-dosed ribavirin (genotype 2), or…
- Trial name
- TAC (NCT02405013)
- Testing
- Sofosbuvir, Ribavirin, Ledipasvir
- Where
- 4 sites in Cameroon, Côte d’Ivoire and 1 more
- Volunteers
- 120 people
- Sponsor
- ANRS, Emerging Infectious Diseases
IFN-Gamma Therapy, CGD Gene Mutation
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Background: Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi.
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease
- Trial name
- NCT01147042
- Testing
- IFN-gamma
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
Effect of IFN-γ on Innate Immune Cells
The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune*) in vivo will display enhanced function across a broad range of activities related in large…
- Trial name
- NCT02609932
- Testing
- Administration of drug (Interferon-gamma 1-b) subcutaneously
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HTLV-I Infection, Spinal Cord Disease
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
HTLV stands for human T cell leukemia virus. HTLV-1 is a virus that attacks specific kinds of white blood cells called T cells. T cells are part of the natural defense system of the body.
- Conditions
- HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
- Trial name
- NCT00001785
- Testing
- Recombinant human interferon beta-1a
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Meningitis, Cryptococcal, HIV Infections
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.
- Trial name
- NCT00012467
- Testing
- Itraconazole, Flucytosine, Fluconazole
- Where
- 9 sites in United States, Peru
- Volunteers
- 60 people
- Sponsor
- InterMune
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
HIV, HIV/AIDS
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)
This study will evaluate the safety, tolerability and innate immune mechanisms activation following administration of the combination of Pegylated Interferon alpha 2b (peg-IFN-α2b) with two broadly neutralizing antibodies…
- Conditions
- HIV, HIV/AIDS, HIV-1 Infection
- Trial name
- BEAT-2 (NCT03588715)
- Testing
- Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Luis Montaner
Hepatitis C Virus (HCV)
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with compensated cirrhosis with or without human…
- Trial name
- VOYAGE-2 (NCT03235349)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 34 sites in China, South Korea
- Volunteers
- 160 people
- Sponsor
- AbbVie
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Hepatitis C, HIV
NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection
The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV (Pegylated Interferon and Ribavirin)-induced anemia In HCV(hepatitis C virus)/HIV…
- Conditions
- Hepatitis C, HIV, Anemia
- Trial name
- NCT00315432
- Testing
- Pegylated Interferon and Ribavirin
- Volunteers
- 91 people
- Sponsor
- Ortho Biotech Products, L.P.
HIV Infections, Immunologic Deficiency Syndromes
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
Patients with congenital or acquired immunodeficiencies are at an increased risk to develop polyclonal or oligoclonal lymphoid malignancies.
- Conditions
- HIV Infections, Immunologic Deficiency Syndromes, Lymphoproliferative Disorders
- Trial name
- NCT00001438
- Testing
- all-trans-retinoic acid with IFN-alpha2a
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, HIV Infections
Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients
The purpose of this study is to determine whether pegylated interferon therapy is effective to treat acute hepatitis C infection in HIV-coinfected individuals.
- Trial name
- NCT00132210
- Testing
- pegylated interferon
- Where
- 14 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital, Bonn
HIV Infections, Hepatitis B
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with hepatitis B virus (HBV), hepatitis C virus (HCV)…
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C
- Trial name
- NCT00051077
- Testing
- Adefovir dipivoxil, Peginterferon-alfa-2A, Ribavirin
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in patients with HIV infection and CD4 count < 400 cells/mm3.
- Trial name
- NCT00000754
- Testing
- Interferon alfa-2a, Zidovudine, Zalcitabine
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV/AIDS
Reducing Proviral HIV DNA With Interferon-a
The purpose of this study is to determine if treatment with pegylated interferon alpha 2b (peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells and tissues of individuals with chronic HIV infection…
- Trial name
- BEAT-HIV (NCT02227277)
- Testing
- Peg-IFN-α2b
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- The Wistar Institute
Sarcoma, Kaposi, HIV Infections
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00000725
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)